Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 894

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 894
---
 ​ | ​ |
| Net increase (decrease) in cash and cash equivalents                                         | ​ | ​ | ​                               | ​ |   1,430 | ​ | ​ | ​ | ​    | ​ | -39,862 | ​ | ​ |
| Cash and cash equivalents–beginning of year                                                  | ​ | ​ | ​                               | ​ |  21,489 | ​ | ​ | ​ | ​    | ​ |  61,351 | ​ | ​ |
| Cash and cash equivalents–end of year                                                        | ​ | ​ | ​                               | $ |  22,919 | ​ | ​ | ​ | ​    | $ |  21,489 | ​ | ​ |
| Non-cash investing and financing activities:                                                 | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Leasehold improvements                                                                       | ​ | ​ | ​                               | $ |       — | ​ | ​ | ​ | ​    | $ |     119 | ​ | ​ |
| Supplemental cash flow information:                                                          | ​ | ​ | ​                               | ​ |       ​ | ​ | ​ | ​ | ​    | ​ |       ​ | ​ | ​ |
| Obtaining an operating lease right-of-use asset in exchange for an operating lease liability | ​ | ​ | ​                               | $ |       — | ​ | ​ | ​ | ​    | $ |     347 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-94

TABLE OF CONTENTS

#### Tvardi Therapeutics, Inc.

### Notes to Financial Statements

### 1. Nature of the Business and Basis of Presentation
Tvardi Therapeutics, Inc., or the Company, incorporated on December 20, 2017, is a Delaware Corporation headquartered in Houston, Texas. The Company is a clinical-stage, biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Based upon its founder’s seminal work and deep understanding of the transcription factor, STAT3, the Company has designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, the Company is developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. The Company’s lead product candidate, T